Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
M Packer, SD Anker, J Butler, G Filippatos… - …, 2021 - hal-emse.ccsd.cnrs.fr
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
M Packer, SD Anker, J Butler, G Filippatos, JP Ferreira… - Circulation, 2020 - europepmc.org
Background Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
M Packer, SD Anker, J Butler, G Filippatos… - …, 2021 - research.regionh.dk
BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
[HTML][HTML] Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
M Packer, SD Anker, J Butler, G Filippatos, JP Ferreira… - Circulation, 2021 - ncbi.nlm.nih.gov
BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
M Packer, SD Anker, J Butler, G Filippatos, JP Ferreira… - 2021 - pubmed.ncbi.nlm.nih.gov
Background Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
M Packer, SD Anker, J Butler, G Filippatos… - …, 2021 - researchonline.lshtm.ac.uk
BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
M Packer, SD Anker, J Butler, G Filippatos, JP Ferreira… - Circulation, 2021 - hal.science
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
M Packer, SD Anker, J Butler, G Filippatos, JP Ferreira… - Circulation, 2021 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> Empagliflozin reduces the risk
of cardiovascular death or hospitalization for heart failure in patients with heart failure and a …
of cardiovascular death or hospitalization for heart failure in patients with heart failure and a …
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
M Packer, SD Anker, J Butler, G Filippatos… - Circulation, 2021 - hal.univ-lorraine.fr
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …
heart failure in patients with heart failure and a reduced ejection fraction, with or without …